Case File
efta-01453444DOJ Data Set 10OtherEFTA01453444
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01453444
Pages
1
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
1d chg (%) Index. WI (%)
BIOGEN IDEC INC
-8.2
7.9
AMGEN INC
-3.2
7.8
Gil F • n SCIENCES INC.
-4.6
7.0
REGENERON PHARMACEUTICALS
-5.4
6.9
CELGENE CORP
-3.7
6.5
ALEXION PHARMACEUTICALS INC
-8.0
4.6
ILLUMINA INC
-5.4
4.6
MYLAN INC
-0.9
4.3
VERTEX PHARMACEUTICALS INC
-5.1
3.8
BIONMIN PHARMACEUTICAL INC
-5.9
2.5
Ways to hedge exposure to the US biotech sector
•
ProShares UltraShort Nasdaq Biotech Fund (BIS US Equity): designed to be 2x short the NBI
•
Options on iSharesNasdaq Biotech ETF (IBB US Equity)
NBI — last 5 ears
2009
2010
2011
2012
300u
2577.21
2000
1500
1000
500
2013
201,
N
kaccaq BlOteCh^t
'J4:4
Copyrighte 2014 alccenterg Finance L.V.
23-Mar-2014 14:3S:20
NBI vs S&P500 — last 1 year
Normalized As Of 03/23/2013
o• NBI Index - SPX Index 38..8807
i s
Jun
NBI — last 1 year
Sep
Dec
Mar
2013
2014
60 "
)8.8807
20 •
0
CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e)
DB-SDNY-0 111026
CONFIDENTIAL
SDNY_GM_00257210
EFTA01453444
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.